Core Viewpoint - The North Exchange 50 Index has reached new historical highs, drawing significant attention from the capital market, with a notable increase in both market performance and investor interest [1][2]. Market Performance - On August 19, the North Exchange 50 Index broke through 1600 points, peaking at 1637.5 points, and closed at 1596.67 points, marking a 1.27% increase [1]. - On August 18, the index surged by 6.79%, closing at 1576.63 points, also a historical high [2]. - Year-to-date, the North Exchange 50 Index has accumulated a rise of 53.85%, with 11 stocks from the exchange increasing over 100% this year, including a notable 226.42% rise for Ge Bi Jia [2]. Fund Performance - All 20 North Exchange thematic funds have reported gains exceeding 39% this year, with an average return of 64.36% [3]. - The top-performing fund, CITIC Securities North Exchange Selected Mixed Fund, achieved returns of 114.59% and 114.06% [3]. - Among the 60 index funds tracking the North Exchange 50 Index, 53 funds have returns exceeding 10%, with 37 funds surpassing 40% [3]. Market Dynamics - The recent performance is attributed to three main factors: the synergy of technology industry trends and policy benefits, the verification of high-growth companies' performance, and improved liquidity and market sentiment [2][4]. - The North Exchange market has seen increased attention and participation since the "9.24" market event, highlighting the innovative capabilities of small and medium-sized enterprises [4]. Investment Strategy - Investors are encouraged to focus on high-growth, high-scarcity, and high-dividend companies within the North Exchange, rather than purely speculative plays [4]. - The North Exchange's market structure and innovative dynamics suggest a promising long-term investment outlook, despite potential short-term volatility [4][5].

Core Viewpoint - The performance of funds in the first half of the year has been significantly influenced by the strong rally in Hong Kong's innovative pharmaceutical sector, with the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, achieving over 85% returns [1][3]. Fund Performance - As of June 30, 2023, the top-performing fund, Huatai-PineBridge Hong Kong Advantage Selection, recorded a return of 86.00% [2][3]. - Other notable funds include CITIC Construction Investment North Exchange Selection and Great Wall Pharmaceutical Industry Selection, with returns of 82.45% and 75.18% respectively [6]. - The overall performance of the Hong Kong stock market, particularly in the innovative pharmaceutical sector, has been robust, with the Hang Seng Index and Hang Seng Technology Index rising by 20% and 18.68% respectively [3]. Market Trends - The innovative pharmaceutical sector in Hong Kong has been a key driver of fund performance, with many funds heavily invested in this area [4][6]. - The Hang Seng Hong Kong Innovative Pharmaceutical Selection Index has seen a year-to-date increase of 58.95%, indicating strong market interest and growth potential [6][7]. - Analysts predict that the innovative pharmaceutical sector will continue to benefit from policy support and market dynamics, suggesting a favorable outlook for the second half of the year [7][8]. Investment Insights - Fund managers believe that the pharmaceutical industry will experience a recovery in growth due to normalized regulations and increasing domestic medical demand [3][4]. - The current market environment is characterized by a combination of policy benefits, global liquidity, and positive market sentiment, which are expected to sustain the growth of innovative pharmaceutical companies [7][8]. - The disparity in fund performance highlights the importance of strategic investment choices, with some funds underperforming despite being in popular sectors [9].